SK1-I hydrochloride BML-258 hydrochloride|cas:2366222-05-9|西域试剂

SK1-I hydrochloride BML-258 hydrochloride,99.49%

产品编号：Bellancom-119016A| CAS NO：2366222-05-9| 分子式：C₁₇H₂₈ClNO₂| 分子量：313.86

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-119016A	￥3500.00	杭州北京（现货）
Bellancom-119016A	￥5800.00	杭州北京（现货）
Bellancom-119016A	￥11000.00	杭州北京（现货）
Bellancom-119016A	￥17000.00	杭州北京（现货）
Bellancom-119016A	￥25000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

SK1-I hydrochloride BML-258 hydrochloride

产品介绍

SK1-I hydrochloride (BML-258 hydrochloride) 是鞘氨醇的类似物，是同功酶特异性 SPHK1 竞争抑制剂，K_i 值为 10 µM。SK1-I hydrochloride 对 SPHK2，PKCα，PKCδ，PKA，AKT1，ERK1，EGFR，CDK2，IKKβ 或 CamK2β 无活性。SK1-I hydrochloride 增强自噬并具有抗肿瘤活性。

生物活性

SK1-I hydrochloride (BML-258 hydrochloride), an analog of sphingosine, is an isozyme-specific competitive SPHK1 inhibitor with a K_i value of 10 µM. SK1-I hydrochloride shows no activity at SPHK1 PKCα, PKCδ, PKA, AKT1, ERK1, EGFR, CDK2, IKKβ or CamK2β. SK1-I hydrochloride enhances autophagy and has antitumor activity.

体外研究

SK1-I hydrochloride (0-10 μM; 24 hours) attenuates cancer cell growth and survival in a TP53-dependent manner in HCT116 cells and HCT116 cells bearing TP53 null cancer.
SK1-I hydrochloride (0-20 μM; 12 hours) induces more CASP3 cleavage in HCT116 cells, compared to HCT116 cells lacking TP53, leading to a hallmark of apoptosis.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	HCT116 cells and HCT116 cells bearing TP53 null cancer
Concentration:	0 µM, 2.5 µM, 5 µM, 7.5 µM, 10 µM
Incubation Time:	24 hours
Result:	Decreased cancer cell growth and survival.

Western Blot Analysis

Cell Line:	HCT116 cells and HCT116 cells bearing TP53 null cancer
Concentration:	0 µM, 5 µM, 10 µM, 20 µM
Incubation Time:	12 hours
Result:	Induced more CASP3 cleavage in HCT116 cells, compared to HCT116 cells lacking TP53.

体内研究
(In Vivo)

Pre-treatment with SK1-I hydrochloride (BML-258 hydrochloride; intraperitoneal (i.p.) injection; once; 24 hours prior to baseline mean arterial blood pressure (MAP) measurement; 75 mg/kg) before anandamide (i.v. injection; two doses; 1 and 10 mg/kg) significantly decreases the hypotensive response.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6 mice (24 ± 3.5 g)
Dosage:	75 mg/kg
Administration:	Intraperitoneal (i.p.) injection; once; 24 hours prior to baseline MAP measurement
Result:	Significantly lowered baseline mean arterial blood pressure (MAP).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6 mice (24 ± 3.5 g)
Dosage:	75 mg/kg
Administration:	Intraperitoneal (i.p.) injection; once; 24 hours prior to baseline MAP measurement
Result:	Significantly lowered baseline mean arterial blood pressure (MAP).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6 mice (24 ± 3.5 g)
Dosage:	75 mg/kg
Administration:	Intraperitoneal (i.p.) injection; once; 24 hours prior to baseline MAP measurement
Result:	Significantly lowered baseline mean arterial blood pressure (MAP).

性状

Liquid

溶解性数据

In Vitro:

DMSO : 250 mg/mL (796.53 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.1861 mL	15.9307 mL	31.8613 mL
5 mM	0.6372 mL	3.1861 mL	6.3723 mL
10 mM	0.3186 mL	1.5931 mL	3.1861 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (6.63 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.63 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (6.63 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.63 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (6.63 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.63 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。